]> 2026-08-07T16:15:41+00:00 Interventional Cardiology News 14 en 2007-10-27T08:30:42Z 2454400.8546528 Interventional Cardiology News Today in Medicine: Implanting the Same vs. Different Drug-Eluting Stent (DES) for the Treatment of DES Restenosis. 0 en Today in Medicine: Implanting the Same vs. Different Drug-Eluting Stent (DES) for the Treatment of DES Restenosis. Today in Medicine: Study Shows Favorable Long-Term Outcomes for DES Implantation in Unprotected Left-main Lesions 0 en Today in Medicine: Study Shows Favorable Long-Term Outcomes for DES Implantation in Unprotected Left-main Lesions Today in Medicine: Mixed Long-term Results for Sirolimus-Eluting Stent Implantation in Diabetic Patients 0 en Today in Medicine: Mixed Long-term Results for Sirolimus-Eluting Stent Implantation in Diabetic Patients RNAPc2 in ACS, Results of ANTHEM-TIMI 32. June 22, 2007 0 en RNAPc2 in ACS, Results of ANTHEM-TIMI 32. June 22, 2007 Stents: Johnson & Johnson Reports Significant Decrease in Stent Sales 0 en Stents: Johnson & Johnson Reports Significant Decrease in Stent Sales Left main coronary artery disease: which stent type is preferred for off-label PCI? 0 en Left main coronary artery disease: which stent type is preferred for off-label PCI? It’s About Time: A Regionalized Approach to Patients with AMI. August 8, 2007 0 en It’s About Time: A Regionalized Approach to Patients with AMI. August 8, 2007 PCI: Nonclinical factors may influence physician decision-making 0 en PCI: Nonclinical factors may influence physician decision-making Remote ischemic preconditioning may improve clinical outcomes after CABG procedure 0 en Remote ischemic preconditioning may improve clinical outcomes after CABG procedure Zotarolimus-Eluting stent Non-Inferior to the Paclitaxel-Eluting Stent in Target Vessel Failure, but a Trend Toward Higher Stent Thrombosis is Observed with Zotarolimus: Results of ENDEAVOR 4 Trial 0 en Zotarolimus-Eluting stent Non-Inferior to the Paclitaxel-Eluting Stent in Target Vessel Failure, but a Trend Toward Higher Stent Thrombosis is Observed with Zotarolimus: Results of ENDEAVOR 4 Trial Western Denmark Registry demonstrates lower risk of thrombosis for Cypher stent 0 en Western Denmark Registry demonstrates lower risk of thrombosis for Cypher stent XIENCE V One Year Data Presented at TCT 2007 0 en XIENCE V One Year Data Presented at TCT 2007 New randomized comparison of unprotected left main coronary artery stenting and CABG 0 en New randomized comparison of unprotected left main coronary artery stenting and CABG Paclitaxel eluting stents are safe and effective in diabetic patients compared to bare metal stents 0 en Paclitaxel eluting stents are safe and effective in diabetic patients compared to bare metal stents Immediate transfer for PCI after fibrinolysis plus abciximab improves outcome in CARESS-in-AMI trial 0 en Immediate transfer for PCI after fibrinolysis plus abciximab improves outcome in CARESS-in-AMI trial TRITON-TIMI 38 stent analysis demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis 0 en TRITON-TIMI 38 stent analysis demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis Platelet monitoring can improve outcomes following PCI among clopidogrel resistant patients 0 en Platelet monitoring can improve outcomes following PCI among clopidogrel resistant patients Percutaneous Coronary Interventions can be performed in centers without on-site cardiac surgical back-up 0 en Percutaneous Coronary Interventions can be performed in centers without on-site cardiac surgical back-up High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry 0 en High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry Removal of debris from the coronary arteries does not improve outcomes: Results from the A-F study 0 en Removal of debris from the coronary arteries does not improve outcomes: Results from the A-F study Thrombus aspiration in patients with ST elevation myocardial infarction improves mortality at 1 year in the TAPAS trial 0 en Thrombus aspiration in patients with ST elevation myocardial infarction improves mortality at 1 year in the TAPAS trial High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events 0 en High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events Left main stenting is associated with similar rates of death, Q wave myocardial infarction and stroke compared with CABG at 3-year follow-up 0 en Left main stenting is associated with similar rates of death, Q wave myocardial infarction and stroke compared with CABG at 3-year follow-up Long Term Adherence to Clopidogrel and Late Adverse Cardiac Events after Off-Label Use of Sirolimus-Eluting Stents: Results of the MATRIX Registry 0 en Long Term Adherence to Clopidogrel and Late Adverse Cardiac Events after Off-Label Use of Sirolimus-Eluting Stents: Results of the MATRIX Registry PEPCAD II ISR study suggests that drug eluting balloons are safe and effective compared with drug eluting stents in treating in-stent restenosis 0 en PEPCAD II ISR study suggests that drug eluting balloons are safe and effective compared with drug eluting stents in treating in-stent restenosis The GENESIS Trial Demonstrates Disappointing Results With Pimecrolimus Eluting Stents 0 en The GENESIS Trial Demonstrates Disappointing Results With Pimecrolimus Eluting Stents The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study 0 en The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study The EVEREST trial suggests MitraClip® for mitral regurgitation is effective 0 en The EVEREST trial suggests MitraClip® for mitral regurgitation is effective Similar nephrotoxic effects with iodixanol and iomeprol in the CONTRAST trial 0 en Similar nephrotoxic effects with iodixanol and iomeprol in the CONTRAST trial The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No Benefit Over Medical Therapy in Patients with Renal Arterial Stenoses 0 en The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No Benefit Over Medical Therapy in Patients with Renal Arterial Stenoses Reloading With Clopidogrel Improves Clinical Outcomes in Patients with Acute Coronary Syndromes: ARMYDA-RELOAD 0 en Reloading With Clopidogrel Improves Clinical Outcomes in Patients with Acute Coronary Syndromes: ARMYDA-RELOAD Implantation of skeletal myoblasts into scarred myocardium improves symptoms but not heart function 0 en Implantation of skeletal myoblasts into scarred myocardium improves symptoms but not heart function High dose tirofiban and clopidogrel are safe and effective in the ON-TIME-2 trial 0 en High dose tirofiban and clopidogrel are safe and effective in the ON-TIME-2 trial WikiDoc News: Stories Submitted for Publication 0 en WikiDoc News: Stories Submitted for Publication The 2009 SCAI Annual Scientific Sessions is to be held in Las Vegas 0 en The 2009 SCAI Annual Scientific Sessions is to be held in Las Vegas NOBORI™ stent is non-inferior to Taxus® stents in the NOBORI 1 trial 0 en NOBORI™ stent is non-inferior to Taxus® stents in the NOBORI 1 trial Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial 0 en Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial Landmark analysis of the TRITON-TIMI 38 trial demonstrates significant benefit with the loading and maintenance doses of prasugrel 0 en Landmark analysis of the TRITON-TIMI 38 trial demonstrates significant benefit with the loading and maintenance doses of prasugrel Time to Abandon Facilitated PCI: Results from the FINESSE trial 0 en Time to Abandon Facilitated PCI: Results from the FINESSE trial Upstream Pharmacotherapy not Superior to Cath Lab Based Therapy in Primary PCI: Results from the FINESSE Trial 0 en Upstream Pharmacotherapy not Superior to Cath Lab Based Therapy in Primary PCI: Results from the FINESSE Trial Successful PCI for Chronic Total Occlusion of the LAD is Associated with Improved Long-term Survival 0 en Successful PCI for Chronic Total Occlusion of the LAD is Associated with Improved Long-term Survival Intracoronary abciximab is superior to intravenous infusion in reducing infarct size during primary PCI 0 en Intracoronary abciximab is superior to intravenous infusion in reducing infarct size during primary PCI Low-risk Women with Unstable Angina and NSTEMI Might be Better off with Medical Therapy than Invasive Treatment 0 en Low-risk Women with Unstable Angina and NSTEMI Might be Better off with Medical Therapy than Invasive Treatment The On-Time 2 trial Suggests Benefit with Early Administration of Tirofiban in the Ambulance following Acute Myocardial Infarction. 0 en The On-Time 2 trial Suggests Benefit with Early Administration of Tirofiban in the Ambulance following Acute Myocardial Infarction. Revascularization with CABG or PCI had no Difference on Outcomes of Death, non-fatal MI, or CVA for Diabetics with Multi-Vessel Coronary Disease: Results of the CARDia Trial 0 en Revascularization with CABG or PCI had no Difference on Outcomes of Death, non-fatal MI, or CVA for Diabetics with Multi-Vessel Coronary Disease: Results of the CARDia Trial HDB Tirofiban decreases rate of periprocedural myocardial infarction compared to placebo in patients with poor responsiveness to clopidogrel and aspirin: Results of the 3T/2R study 0 en HDB Tirofiban decreases rate of periprocedural myocardial infarction compared to placebo in patients with poor responsiveness to clopidogrel and aspirin: Results of the 3T/2R study High dose Tirofiban Might be Beneficial among Poor Responders to Clopidogrel and Aspirin Following Elective PCI: Results of the 3T/2R study 0 en High dose Tirofiban Might be Beneficial among Poor Responders to Clopidogrel and Aspirin Following Elective PCI: Results of the 3T/2R study Intracoronary infusion of selected and unselected mononuclear cells does not lead to significant improvement in cardiac function after sustained ischemia: Results from the REGENT trial 0 en Intracoronary infusion of selected and unselected mononuclear cells does not lead to significant improvement in cardiac function after sustained ischemia: Results from the REGENT trial HDB Tirofiban decreases rate of periprocedural myocardial infarction compared to placebo in patients with poor responsiveness to clopidogrel and aspirin: Results of the 3T/2R study 0 en HDB Tirofiban decreases rate of periprocedural myocardial infarction compared to placebo in patients with poor responsiveness to clopidogrel and aspirin: Results of the 3T/2R study High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events 0 en High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events High dose Tirofiban Might be Beneficial among Poor Responders to Clopidogrel and Aspirin Following Elective PCI: Results of the 3T/2R study 0 en High dose Tirofiban Might be Beneficial among Poor Responders to Clopidogrel and Aspirin Following Elective PCI: Results of the 3T/2R study High dose tirofiban and clopidogrel are safe and effective in the ON-TIME-2 trial 0 en High dose tirofiban and clopidogrel are safe and effective in the ON-TIME-2 trial High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry 0 en High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry Immediate transfer for PCI after fibrinolysis plus abciximab improves outcome in CARESS-in-AMI trial 0 en Immediate transfer for PCI after fibrinolysis plus abciximab improves outcome in CARESS-in-AMI trial Implantation of skeletal myoblasts into scarred myocardium improves symptoms but not heart function 0 en Implantation of skeletal myoblasts into scarred myocardium improves symptoms but not heart function Intracoronary abciximab is superior to intravenous infusion in reducing infarct size during primary PCI 0 en Intracoronary abciximab is superior to intravenous infusion in reducing infarct size during primary PCI Intracoronary infusion of selected and unselected mononuclear cells does not lead to significant improvement in cardiac function after sustained ischemia: Results from the REGENT trial 0 en Intracoronary infusion of selected and unselected mononuclear cells does not lead to significant improvement in cardiac function after sustained ischemia: Results from the REGENT trial It’s About Time: A Regionalized Approach to Patients with AMI. August 8, 2007 0 en It’s About Time: A Regionalized Approach to Patients with AMI. August 8, 2007 Landmark analysis of the TRITON-TIMI 38 trial demonstrates significant benefit with the loading and maintenance doses of prasugrel 0 en Landmark analysis of the TRITON-TIMI 38 trial demonstrates significant benefit with the loading and maintenance doses of prasugrel Left main coronary artery disease: which stent type is preferred for off-label PCI? 0 en Left main coronary artery disease: which stent type is preferred for off-label PCI? Left main stenting is associated with similar rates of death, Q wave myocardial infarction and stroke compared with CABG at 3-year follow-up 0 en Left main stenting is associated with similar rates of death, Q wave myocardial infarction and stroke compared with CABG at 3-year follow-up Long Term Adherence to Clopidogrel and Late Adverse Cardiac Events after Off-Label Use of Sirolimus-Eluting Stents: Results of the MATRIX Registry 0 en Long Term Adherence to Clopidogrel and Late Adverse Cardiac Events after Off-Label Use of Sirolimus-Eluting Stents: Results of the MATRIX Registry Low-risk Women with Unstable Angina and NSTEMI Might be Better off with Medical Therapy than Invasive Treatment 0 en Low-risk Women with Unstable Angina and NSTEMI Might be Better off with Medical Therapy than Invasive Treatment NOBORI™ stent is non-inferior to Taxus® stents in the NOBORI 1 trial 0 en NOBORI™ stent is non-inferior to Taxus® stents in the NOBORI 1 trial New randomized comparison of unprotected left main coronary artery stenting and CABG 0 en New randomized comparison of unprotected left main coronary artery stenting and CABG PCI: Nonclinical factors may influence physician decision-making 0 en PCI: Nonclinical factors may influence physician decision-making PEPCAD II ISR study suggests that drug eluting balloons are safe and effective compared with drug eluting stents in treating in-stent restenosis 0 en PEPCAD II ISR study suggests that drug eluting balloons are safe and effective compared with drug eluting stents in treating in-stent restenosis Paclitaxel eluting stents are safe and effective in diabetic patients compared to bare metal stents 0 en Paclitaxel eluting stents are safe and effective in diabetic patients compared to bare metal stents Percutaneous Coronary Interventions can be performed in centers without on-site cardiac surgical back-up 0 en Percutaneous Coronary Interventions can be performed in centers without on-site cardiac surgical back-up Platelet monitoring can improve outcomes following PCI among clopidogrel resistant patients 0 en Platelet monitoring can improve outcomes following PCI among clopidogrel resistant patients RNAPc2 in ACS, Results of ANTHEM-TIMI 32. June 22, 2007 0 en RNAPc2 in ACS, Results of ANTHEM-TIMI 32. June 22, 2007 Reloading With Clopidogrel Improves Clinical Outcomes in Patients with Acute Coronary Syndromes: ARMYDA-RELOAD 0 en Reloading With Clopidogrel Improves Clinical Outcomes in Patients with Acute Coronary Syndromes: ARMYDA-RELOAD Remote ischemic preconditioning may improve clinical outcomes after CABG procedure 0 en Remote ischemic preconditioning may improve clinical outcomes after CABG procedure Removal of debris from the coronary arteries does not improve outcomes: Results from the A-F study 0 en Removal of debris from the coronary arteries does not improve outcomes: Results from the A-F study Revascularization with CABG or PCI had no Difference on Outcomes of Death, non-fatal MI, or CVA for Diabetics with Multi-Vessel Coronary Disease: Results of the CARDia Trial 0 en Revascularization with CABG or PCI had no Difference on Outcomes of Death, non-fatal MI, or CVA for Diabetics with Multi-Vessel Coronary Disease: Results of the CARDia Trial Similar nephrotoxic effects with iodixanol and iomeprol in the CONTRAST trial 0 en Similar nephrotoxic effects with iodixanol and iomeprol in the CONTRAST trial Stents: Johnson & Johnson Reports Significant Decrease in Stent Sales 0 en Stents: Johnson & Johnson Reports Significant Decrease in Stent Sales Successful PCI for Chronic Total Occlusion of the LAD is Associated with Improved Long-term Survival 0 en Successful PCI for Chronic Total Occlusion of the LAD is Associated with Improved Long-term Survival TRITON-TIMI 38 stent analysis demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis 0 en TRITON-TIMI 38 stent analysis demonstrates that prasugrel is better than clopidogrel in reducing the incidence of early and late stent thrombosis The 2009 SCAI Annual Scientific Sessions is to be held in Las Vegas 0 en The 2009 SCAI Annual Scientific Sessions is to be held in Las Vegas The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No Benefit Over Medical Therapy in Patients with Renal Arterial Stenoses 0 en The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No Benefit Over Medical Therapy in Patients with Renal Arterial Stenoses The EVEREST trial suggests MitraClip® for mitral regurgitation is effective 0 en The EVEREST trial suggests MitraClip® for mitral regurgitation is effective The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study 0 en The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study The GENESIS Trial Demonstrates Disappointing Results With Pimecrolimus Eluting Stents 0 en The GENESIS Trial Demonstrates Disappointing Results With Pimecrolimus Eluting Stents The On-Time 2 trial Suggests Benefit with Early Administration of Tirofiban in the Ambulance following Acute Myocardial Infarction. 0 en The On-Time 2 trial Suggests Benefit with Early Administration of Tirofiban in the Ambulance following Acute Myocardial Infarction. Thrombus aspiration in patients with ST elevation myocardial infarction improves mortality at 1 year in the TAPAS trial 0 en Thrombus aspiration in patients with ST elevation myocardial infarction improves mortality at 1 year in the TAPAS trial Time to Abandon Facilitated PCI: Results from the FINESSE trial 0 en Time to Abandon Facilitated PCI: Results from the FINESSE trial Today in Medicine: Implanting the Same vs. Different Drug-Eluting Stent (DES) for the Treatment of DES Restenosis. 0 en Today in Medicine: Implanting the Same vs. Different Drug-Eluting Stent (DES) for the Treatment of DES Restenosis. Today in Medicine: Mixed Long-term Results for Sirolimus-Eluting Stent Implantation in Diabetic Patients 0 en Today in Medicine: Mixed Long-term Results for Sirolimus-Eluting Stent Implantation in Diabetic Patients Today in Medicine: Study Shows Favorable Long-Term Outcomes for DES Implantation in Unprotected Left-main Lesions 0 en Today in Medicine: Study Shows Favorable Long-Term Outcomes for DES Implantation in Unprotected Left-main Lesions Upstream Pharmacotherapy not Superior to Cath Lab Based Therapy in Primary PCI: Results from the FINESSE Trial 0 en Upstream Pharmacotherapy not Superior to Cath Lab Based Therapy in Primary PCI: Results from the FINESSE Trial Western Denmark Registry demonstrates lower risk of thrombosis for Cypher stent 0 en Western Denmark Registry demonstrates lower risk of thrombosis for Cypher stent WikiDoc News: Stories Submitted for Publication 0 en WikiDoc News: Stories Submitted for Publication XIENCE V One Year Data Presented at TCT 2007 0 en XIENCE V One Year Data Presented at TCT 2007 Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial 0 en Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial Zotarolimus-Eluting stent Non-Inferior to the Paclitaxel-Eluting Stent in Target Vessel Failure, but a Trend Toward Higher Stent Thrombosis is Observed with Zotarolimus: Results of ENDEAVOR 4 Trial 0 en Zotarolimus-Eluting stent Non-Inferior to the Paclitaxel-Eluting Stent in Target Vessel Failure, but a Trend Toward Higher Stent Thrombosis is Observed with Zotarolimus: Results of ENDEAVOR 4 Trial INST 102 en INST